Dermira Inc. (NASDAQ:DERM) saw unusually-strong trading volume on Tuesday . Approximately 363,400 shares traded hands during mid-day trading, an increase of 50% from the previous session’s volume of 242,719 shares.The stock last traded at $36.00 and had previously closed at $35.03.

Several equities analysts have recently weighed in on DERM shares. Zacks Investment Research upgraded Dermira from a “sell” rating to a “hold” rating in a research report on Tuesday, June 14th. Leerink Swann reiterated a “buy” rating and issued a $47.00 price target (up from $46.00) on shares of Dermira in a research report on Thursday, June 2nd. Wedbush lifted their price target on Dermira from $42.00 to $46.00 and gave the company an “outperform” rating in a research report on Thursday, June 2nd. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $46.00 price target on shares of Dermira in a research report on Wednesday, June 22nd. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $41.00.

The stock’s 50 day moving average is $32.35 and its 200-day moving average is $28.45. The firm’s market capitalization is $1.26 billion.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/dermira-inc-derm-sees-large-volume-increase.html

Dermira (NASDAQ:DERM) last released its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by $0.03. On average, equities research analysts expect that Dermira Inc. will post ($3.39) EPS for the current fiscal year.

In related news, VP Christopher M. Griffith sold 1,303 shares of the company’s stock in a transaction that occurred on Friday, July 15th. The stock was sold at an average price of $30.02, for a total value of $39,116.06. Following the transaction, the vice president now directly owns 44,941 shares of the company’s stock, valued at approximately $1,349,128.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Luis C. Pena sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, June 23rd. The shares were sold at an average price of $30.01, for a total value of $300,100.00. Following the completion of the transaction, the insider now directly owns 14,653 shares in the company, valued at $439,736.53. The disclosure for this sale can be found here. 17.30% of the stock is owned by corporate insiders.

Institutional investors have recently added to or reduced their stakes in the stock. FMR LLC boosted its position in Dermira by 29.3% in the second quarter. FMR LLC now owns 4,063,136 shares of the biopharmaceutical company’s stock valued at $118,847,000 after buying an additional 921,800 shares during the last quarter. Jennison Associates LLC boosted its position in Dermira by 52.0% in the second quarter. Jennison Associates LLC now owns 2,514,166 shares of the biopharmaceutical company’s stock valued at $73,539,000 after buying an additional 860,597 shares during the last quarter. TimesSquare Capital Management LLC boosted its position in Dermira by 79.3% in the second quarter. TimesSquare Capital Management LLC now owns 2,491,526 shares of the biopharmaceutical company’s stock valued at $72,877,000 after buying an additional 1,101,645 shares during the last quarter. Eagle Asset Management Inc. boosted its position in Dermira by 4.3% in the second quarter. Eagle Asset Management Inc. now owns 1,344,721 shares of the biopharmaceutical company’s stock valued at $39,333,000 after buying an additional 55,991 shares during the last quarter. Finally, BlackRock Fund Advisors boosted its position in Dermira by 13.3% in the second quarter. BlackRock Fund Advisors now owns 1,196,544 shares of the biopharmaceutical company’s stock valued at $34,999,000 after buying an additional 140,333 shares during the last quarter. 82.46% of the stock is currently owned by institutional investors and hedge funds.

About Dermira

Dermira, Inc is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01.

5 Day Chart for NASDAQ:DERM

Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.